Lycia Therapeutics (NASDAQ:LYCA) Stock: Insider Venrock Healthcare Capital Par Acquires 1,000 Shares

Lycia Therapeutics, Inc. (NASDAQ:LYCA) major shareholder Venrock Healthcare Capital Par purchased 1,000 shares of the stock in a transaction that occurred on Thursday, October 29th. The stock was bought at an average cost of $26.33 per share, with a total value of $26,330.00. Following the acquisition, the insider owned 6,841,233 shares of the company’s stock, valued at $180,129,664.89. This represents a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, October 30th, Venrock Healthcare Capital Par acquired 9,004 shares of Lycia Therapeutics stock. The stock was bought at an average price of $26.28 per share, with a total value of $236,625.12.
• On Wednesday, October 28th, Venrock Healthcare Capital Par acquired 15,000 shares of Lycia Therapeutics stock. The stock was bought at an average price of $25.45 per share, with a total value of $381,750.00.
• On Tuesday, October 27th, Venrock Healthcare Capital Par acquired 39,796 shares of Lycia Therapeutics stock. The stock was purchased at an average price of $26.62 per share, for a total transaction of $1,059,369.52.
• On Monday, October 26th, Venrock Healthcare Capital Par acquired 1,952,705 shares of Lycia Therapeutics stock. The stock was purchased at an average price of $18.04 per share, for a total transaction of $35,226,798.20.
• On Friday, October 23rd, Venrock Healthcare Capital Par bought 52,939 shares of Lycia Therapeutics stock. The stock was purchased at an average cost of $25.91 per share, with a total value of $1,371,649.49.

Lycia Therapeutics Price Performance

LYCA stock opened at $26.40 on Friday. Lycia Therapeutics, Inc. has a twelve month low of $22.19 and a twelve month high of $36.49.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Lycia Therapeutics to a “hold” rating in a research report on Saturday.

About Lycia Therapeutics

Lycia Therapeutics, Inc is a biotechnology company developing medicines designed to eliminate disease-causing proteins from cells. The company’s approach is based on lysosome-targeting chimeras, or LYTACs, which are engineered molecules intended to direct extracellular and cell-surface proteins to lysosomes for degradation.

Lycia’s technology is intended to address disease targets that may be difficult to inhibit with conventional drugs, including proteins located outside cells or embedded in cell membranes.